TRCT
SCPS

Tower Research Capital (TRC)’s Scopus BioPharma Inc. Common Stock SCPS Stock Holding History

Tower Research Capital (TRC)’s Portfolio SCPS Stock Details SCPS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-26,533
Closed -$6K – 6781
2022
Q3 		$6K Sell
26,533
-1,625
-6% -$590 ﹤0.01% 5106
2022
Q2 		$12K Buy
28,158
+18,971
+206% +$9.12K ﹤0.01% 4338
2022
Q1 		$6K Buy
9,187
+3,450
+60% +$3.33K ﹤0.01% 4991
2021
Q4 		$9K Sell
5,737
-16,981
-75% -$51.5K ﹤0.01% 4758
2021
Q3 		$94K Buy
22,718
+19,883
+701% +$102K ﹤0.01% 2461
2021
Q2 		$20K Buy
2,835
+2,638
+1,339% +$18.8K ﹤0.01% 3912
2021
Q1 		$2K Sell
197
-1,173
-86% -$12.3K ﹤0.01% 5091
2020
Q4 		$20K Buy
+1,370
New +$24.3K ﹤0.01% 3890

Other funds holding SCPS

MRCM
M&R Capital Management Summit, New Jersey $454M AUM 40.11% 1-Year Est. Return

Tower Research Capital (TRC)'s SCPS Position: Q4 2022 in Review

Tower Research Capital (TRC) sold out of Scopus BioPharma Inc. Common Stock (SCPS) in Q4 2022, closing a stake of 26,533 shares — an estimated $6K sold.

Tower Research Capital (TRC) first reported a position in SCPS in Q4 2020 and held it in 8 quarters. The position peaked at $94K in Q3 2021. 1 fund tracked by Wall St. Rank holds SCPS as of Q4 2022.

  • Tower Research Capital (TRC) reported no remaining Scopus BioPharma Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 26,533 Scopus BioPharma Inc. Common Stock shares in Q4 2022, an estimated $6K.
  • Tower Research Capital (TRC) first reported a position in Scopus BioPharma Inc. Common Stock in Q4 2020 and held it in 8 quarters.
  • Tower Research Capital (TRC)'s Scopus BioPharma Inc. Common Stock position peaked at $94K in Q3 2021.
  • 1 fund tracked by Wall St. Rank held Scopus BioPharma Inc. Common Stock as of Q4 2022.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2022, filed 10 Feb 2023.